Podcast Archives

The Aducanumab Aftermath: The Payer

A costly new Alzheimer’s drug could wreak financial havoc on insurers, seniors and taxpayers.

One patient shares her hopes and concerns about a costly new Alzheimer’s drug.

One doctor grapples with questions about a controversial new Alzheimer’s drug’s safety and efficacy.

Health economist Kosali Simon shares conference tips, stories and abstracts she’s excited for at AcademyHealth and ASHEcon.

From the fear of shutting down to the exhaustion of reopening and the missed appointments in between.

The FDA weighs whether to approve a controversial new Alzheimer’s drug.

Doctors are pushing millions more Americans to get screened for lung cancer, but the test comes with tricky risks and tough barriers.

We dig into the research to help employers weigh the pros and cons of requiring their employees to get vaccinated.

In this live episode, policy experts and employers debate the best way to improve employer-based health insurance.

While states experiment with public health insurance options, federal action has stalled.